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Formation of a Proinflammatory Environment to Allow
Crosstalk and High Avidity Interaction with
Nonhematopoietic Tissues to Induce GVHD Reactivity
Boris van der Zouwen,1 Alwine B. Kruisselbrink,1
Ekaterina S. Jordanova,2 Caroline E. Rutten,1 Peter A. von dem Borne,1
J. H. Frederik Falkenburg,1 Inge Jedema1Based on clinical observations that donor T cells specific for minor histocompatibility antigens (MiHA) ubiq-
uitously expressed on both hematopoietic and nonhematopoietic cells were detected in patients showing ev-
ident graft-versus-leukemia/lymphoma (GVL) reactivity with no or limited coinciding graft-versus-host
disease (GVHD), we hypothesized that nonhematopoietic tissues may be relatively unsusceptible to the
cytotoxic effect of MiHA-specific T cells under normal, noninflammatory conditions. To test this hypothesis,
we investigated the reactivity of alloreactive T cells specific for ubiquitously expressed MiHA against skin-
derived primary human fibroblasts.We demonstrated that this reactivity was not merely determined by their
antigen-specificity, but was highly dependent on adhesion molecule expression. ICAM-1 expression on the
fibroblasts upregulated under proinflammatory conditions and induced during cross-talk with the T cells
was demonstrated to be a crucial factor facilitating formation of high avidity interactions with the T cells
and subsequent efficient target cell destruction. Furthermore, we provide supporting evidence for the role
of ICAM-1 in vivo by demonstrating that ICAM-1 expression on nonhematopoietic target cells was dependent
on the presence of infiltrating activated T cells, as was illustrated by restricted ICAM-1 expression at the sites
of T cell infiltration in skin biopsies of patients with acuteGVHD (aGVHD), by the absence of ICAM-1 expres-
sion in the same biopsies in areas without T cell infiltration and by the absence of ICAM-1 expression in
biopsies of patients without GVHD independent of the presence of infiltrating nonactivated T cells. In con-
clusion, under noninflammatory conditions, nonhematopoietic tissues are unsusceptible to the GVHD
reactivity of alloreactive T cells due to their inability to establish high avidity interactions.
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oi.org/10.1016/j.bbmt.2012.06.017matological cancers [1,2]. After HLA-matched allo
SCT, donor T cells can recognize patient cells as for-
eign, due to the expression of specific minor histocom-
patibility antigens (MiHA) [3-5]. Donor T cells
recognizing MiHA specifically expressed on recipient
hematopoietic cells, including the malignant cells,
can mediate a therapeutic graft-versus-leukemia/
lymphoma (GVL) effect [2,3,6-9]. However, donor
T cells recognizing polymorphic peptides presented
on normal nonhematopoietic tissues from the
recipient may also mediate graft-versus-host disease
(GVHD), which is the main cause of morbidity and
mortality after alloSCT [10-12].
Surprisingly, high frequencies of circulating T cells
expressing specificT cell receptors with high affinity for
MiHA with ubiquitous expression in both hematopoi-
etic and nonhematopoietic tissues have been detected
in patients showing a strong GVL reaction in the1353
1354 Biol Blood Marrow Transplant 18:1353-1367, 2012B. van der Zouwen et al.absence ofGVHDorwith only limitedGVHD[13-15].
These clinical data suggest that nonhematopoietic
tissues are not always targeted by high affinity
cytotoxic MiHA-specific T cells despite expression of
the antigen. In contrast, in other studies, a clear corre-
lation between the presence of T cells directed against
ubiquitously expressed MiHA and the occurrence of
GVHD has been suggested [16-18]. Intriguingly,
Warren et al. [19] demonstrated that adoptive transfer
of MiHA-specific donor T cells, even after in vitro de-
pletion for reactivity against patient-derived fibroblasts,
resulted in significant GVHD induction in vivo. Appar-
ently, other factors besides expression of theMiHA also
determine the susceptibility to T cell attack of nonhe-
matopoietic target cells.
Efficient T cell-mediated cytolysis of (nonhemato-
poietic) target cells in vitro requires the formation of
high avidity interactions between the immune effector
cells and the target cells [20,21]. This avidity is
determined by multiple factors, including the affinity
of the T cell receptor of the effector cell, the level of
expression of relevant peptide/MHC complexes on
the target cell surface, and the expression of adhesion
molecules, such as ICAM-1 [22-29]. In vivo, the local
cytokine milieu most likely dictates the expression of
molecules involved in the formation of a high avidity
interaction between immune effector cells and
nonhematopoietic target cells [24,30]. Investigations
in mouse models demonstrated that conditioning
and underlying diseases may damage host tissues
resulting in production of so-called danger signals, in-
cluding proinflammatory cytokines, chemokines, and
amplified expression of adhesion molecules, MHC an-
tigens, and costimulatory molecules on host tissue,
thereby rendering these tissues more sensitive to
T cell attack [11,31,32].
We hypothesized that in vivo the formation of a lo-
cal proinflammatory cytokine milieu by locally acti-
vated T cells and subsequent sensitization of the
surrounding nonhematopoietic cells to T cell attack
determines whether or not GVHD is induced by
T cells directed against ubiquitously expressed
MiHA. In the current study, we demonstrate that the
reactivity against skin-derived primary human fibro-
blasts of these T cells under noninflammatory, steady
state conditions is low due to their inability to form
a high avidity interaction. However, under proinflam-
matory circumstances, high avidity interactions are
formed resulting in efficient targeting of the fibroblasts
by the MiHA-specific T cells. ICAM-1 is demon-
strated to be a key molecule mediating the high avidity
interaction between T cells and nonhematopoietic tar-
get cells necessary for execution of their effector func-
tion, which is supported by the demonstration of
co-localization of massive T cell infiltrates and up-
regulated ICAM-1 expression on the epithelial cells
of the basal layer in skin biopsies of patients with acuteGVHD (aGVHD). This study illustrates that in vivo
reactivity of MiHA-specific T cells leading to
GVHD cannot solely be predicted based on their anti-
gen specificity. Under circumstances in which the
magnitude of the immune response does not cause a lo-
cal proinflammatory environment in the GVHD tar-
get tissues, targeting of MiHA with broad expression
profiles may result in specific GVL reactivity without
GVHD.On the other hand, absence of in vitro reactiv-
ity against patient nonhematopoietic tissues, as mea-
sured under noninflammatory conditions, does not
guarantee protection against GVHD induction under
clinical circumstances resulting in a local proinflam-
matory environment, which increases the susceptibil-
ity of cells in GVHD target tissues.MATERIALS AND METHODS
Target Cells
After informed consent, primary human fibroblasts
were generated from skin biopsies from patients or
healthy donors. The skin biopsies were washed with
PBS, minced, and transferred to 6-well culture plates
containing low-glucose Dulbecco’s modified Eagle
medium (Lonza, Verviers, Belgium) supplemented
with 10% FBS (Invitrogen, Breda, The Netherlands).
Fibroblasts were cultured up to 90% confluency and
then harvested using trypsin (Lonza, Verviers, Bel-
gium) for 7 minutes at 37C, followed by 2 washing
steps. Stock samples were cryopreserved in liquid ni-
trogen. After thawing, the samples were reseeded at
a concentration of 5000 cells/cm2 and cultured again
to 90% confluency, harvested, and reseeded. Experi-
ments were performed using fibroblasts cultured for
5 to 20 passages. In specific experiments, fibroblasts
were pretreated for 2 days with IFNgamma (IFNg;
200 IU/mL; Boehringer Ingelheim, Alkmaar, The
Netherlands). In specific experiments, transduced
fibroblasts were used. These fibroblasts were retro-
virally transduced with pLZRS-constructs encod-
ing HLA-A*0201, ICAM-1 (kindly provided by
Dr. E.Hooijberg, VUMC, Amsterdam), or empty vec-
tor (mock), linked to the truncated human nerve
growth factor receptor (NGFR) selection marker
gene via an internal ribosome entry site sequence
[33-35]. The identity of all constructs was verified by
sequencing. Retroviral supernatants were generated
with phoenix packaging (F-NX-A) cells, as
previously described, and used for transduction of
fibroblasts using recombinant human fibronectin
fragments CH-296 (Lonza, Verviers, Belgium) [33].
Mock, ICAM-1, and HLA-A*0201-transduced
fibroblasts were stained with NGFR-PE and puri-
fied by magnetic bead separation using anti-PE beads
according to manufacturer’s instructions (Milteny
Biotec, Bergish Gladbach, Germany). Stable
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(EBV-LCL) were cultured in Iscove’s modified Dul-
becco’s medium (IMDM; Lonza, Verviers, Belgium)
supplemented with 10% FBS. Adherent solid tumor
cell lines from colorectal adenocarcinoma cell line
(CCL-228; American Type Culture Collection
[ATCC], Manassas, VA) and 2 renal cell carcinoma
(kindly provided by Dr. B. Seliger, Department of In-
ternal Medicine, Mainz, Germany) were cultured in
RPMI supplemented with 10% FBS.
Cytotoxic T Cell Clone Generation and Culture
The cytotoxic CD8 positive T cell clone (CTL)
RDR2, specific for the HLA-A*0201-restricted
MiHA LB-ADIR-1F, was previously isolated from pe-
ripheral blood of a patient at the time of clinical re-
sponse to donor lymphocyte infusion (DLI) as
treatment for relapsedmultiplemyeloma after alloSCT
[14,36]. The HLA-A*0201-restricted SMCY311-319-
HY-specific CTL was isolated from the peripheral
blood of a female patient after rejection of a male
stem cell graft [37]. The allo-HLA-A*0201-specific
CTL MBM13 was isolated in vitro from an HLA-
A*0201 mismatched mixed lymphocyte reaction.
CTL clones were expanded in expansion-medium con-
sisting of IMDM, supplemented with 5% FBS, 5%
pre-screened pooled human serum, and 100 IU/mL
IL-2 (Chiron, Amsterdam, The Netherlands). CTLs
were restimulated using a feeder mixture containing
expansion-medium supplemented with 5 irradiated
(50 Gy) allogeneic mononuclear cells and 0.2 irradi-
ated (50 Gy) allogeneic EBV-LCL, and 0.8 mg/mL
phytohemagglutinin-HA16 (Remel, Dartford, United
Kingdom) every 3 weeks. T cells were used for func-
tional tests at 2 to 3 weeks after restimulation.
Abs and Flowcytometric Analysis
The FITC-labeled mAbs against CD2, CD4,
CD11a, CD15 CD19, CD57, CD58, CD107a, and
HLA-A*0201, the PE-labeled mAbs against CD19,
CD90, CD102, CD103, HLA-A*02, Perforin, and
NGFR, the cyanin-dye-7-coupled R-phycoerythrin
(PE-Cy7)-labeled mAbs against CD3, and the
allophycocyanin-labeled mAbs against CD137 and
CD8 were obtained from Becton Dickinson (San
Jose, CA). FITC-labeled mAbs against CD49D,
CD49E, CD49F, and CD90, and panTCR-PE-Cy7
were obtained from Beckman Coulter (Fullerton,
CA). CD11b-FITC, CD43-FITC, CD54-FITC, and
granzyme-B-PE mAbs were purchased from CLB/
Sanquin (Amsterdam, The Netherlands). FITC-
labeled mAbs against CD18, CD166, and HLA-ABC
were purchased from Serotec (Dusseldorf, Germany).
FITC-labeled mAbs against CD31, CD62L, and
CD62P were purchased from Bender MedSystem
(Vienna, Austria). CD50-PE was purchased fromITK/Biolegend (San Diego, CA), CD62E-FITC
from Bio-Connect (Huissen, The Netherlands), and
CD106 from R&D System (Minneapolis, MN).
allophycocyanin-labeled or PE-labeled tetramers for
MiHA LB-ADIR-1F and SMCY-HY were con-
structed as described [38]. For surface molecule stain-
ing, cells were labeled withmAbs for 30minutes at 4C
in PBS supplemented with 2% pasteurized plasma
protein solution (Sanquin, Amsterdam, The Nether-
lands). For intracellular staining, cells were washed af-
ter surface staining, fixated with paraformaldehyde
(1%), and permeabilized for 30 minutes at 4C using
PBS with 0.1% Saponine (Sigma-Aldrich, Steinheim,
Germany). After permeabilization, cells were stained
with mAbs for intracellular staining for 30 minutes at
4C in PBS-Saponine. Flowcytometric analysis was
performed on a BD flowcytometer using CellquestPro
software and FlowJo software (Treestar, Ashland,
OR). For quantitative fluorescent activated cell sorter
(FACS) analysis, cells were taken up in 75 mL PBS/
2% pasteurized plasma protein solution after surface
staining, and short before performing FACS analysis
0.2 mg/mL propidium iodide and 10,000 flowcount
fluorosphere beads (Beckman-Coulter, Woerden,
The Netherlands) were added. For each sample,
2000 beads were acquired. The numbers of viable fi-
broblasts were calculated by correcting the analyzed
numbers of CD90 positive, propidium iodide negative
cells for the amount of beads.Functional T Cell Analysis
Analysis of T cell activation and degranulation
upon target cell encounter was performed by exposing
10,000 CTLs to fibroblasts or EBV-LCLs at various
responder to stimulator (R/S) ratios (1/0.1-1/10). Su-
pernatants were harvested, and IFNg release was mea-
sured by standard ELISA (Sanquin, Amsterdam, The
Netherlands). In the same samples, the percentages of
degranulating T cells were determined using flowcyto-
metric analysis of CD107a, granzyme-B, and perforin
expression. Analysis of cytotoxicity was performed by
quantitative-FACS analysis or by conventional 51Cr-
release assay, in which target cells were labeled with
50 mCi Na2
51CrO4 (NEZ030005MC 185 MBQ, Per-
kin Elmer) for 1 hour at 37C. In specific experiments,
after labeling target cells were exogenously loaded with
different concentrations (1 pM-1 mM) of the relevant
MiHA peptides (SVAPALALFPA [LB-ADIR-1F] or
FIDSYICQV [SMCY-HY]) for 1 hour at 37C.Target
cells (fibroblasts 1000 cells/well and EBV-LCL 10,000
cells/well) were seeded in 96-well plates together with
MiHA-specific T cells at different effector/target
(E/T)-ratios (100/1-0.01/1) in the presence or absence
of blocking anti-ICAM-1 (CD54) (5 ng/mL) MoAbs
(ITK/Biolegend). After 4, 8, and 20 hours of incuba-
tion, cytotoxicity was measured.
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Primary human fibroblasts were seeded at 50,000
cells per glass bottom dish (P35G-1.5-14-C, MatTek
Corporation) and cultured in Dulbecco’s modified Ea-
glemediumwithout phenolred (Invitrogen, Breda, The
Netherlands) supplemented with 10% FCS. After
3 days, medium was removed and the adherent cells
were washed 3 times with 2 mL IMDMw/o phenolred
(Invitrogen) supplemented with 10% FCS. CTLs were
labeled with 5 mM PKH26 according to the manufac-
turer’s instructions (Sigma-Aldrich) and added to the fi-
broblasts at a 3/1 CTL/fibroblast ratio in IMDM
without phenolred supplemented with 10% FCS and
IL-2 (30 IU/mL). The dishes were incubated for 1 to
2 hours at 37C, followed by analysis of cellular interac-
tions by confocal microscopy using a 488 laser (Leica
TCS SP2 inverted stand DM IRE2 microscope
with PL APO 40 1.25-0.75 with oil, Leica Microsys-
tems Heidelberg, Germany). Series of differential-
interference-contrast images and fluorescent (PKH26)
images were acquired at intervals of 0.5 mm in z-direc-
tion. For each individual sample, 10 positions in the
dish were examined (10 zstacks). Images and videos
were analyzed using Leica Confocal Software/Image J.
Immunohistochemistry
After informed consent, biopsies of involved skin
were obtained from healthy control individuals and
from patients with clinically diagnosed acute skin
GVHD (Lerner 1-2) after HLA-matched alloSCT as
treatment for several hematological malignancies after
myeloablative conditioning (n 5 5). Tissues were fixed
in 10% v/v formalin and embedded in paraffin. Immu-
nohistochemical analysis was performed on 4 mm paraf-
fin sections. Sections were deparaffinized, rehydrated,
and antigen retrieval was performed using 0.01M cit-
rate, pH 6.0, and boiling of the slides for 10 minutes
in a microwave. Triple stainings were performed at
room temperature with mouse monoclonal anti-
human CD3 (clone PS1, IgG2a, 1:50; Abcam, Cam-
bridge, MA), rabbit monoclonal anti-human CD54
(clone EP1442Y, 1:100; Abcam), or mouse monoclonal
anti-human HLA-class II (clone CR3/43, IgG1, 1:50;
Dako Netherlands BV, Heverlee, Belgium), and mouse
or rabbit monoclonal anti-human cytokeratin (clone
AE1/AE3, IgG1, 1:500; Dako) diluted in PBS/1%
BSA (100 mL per sample). The next day, the slides
were washed with PBS and incubated for 1 hour at
room temperature with goat anti-mouse IgG2a ALEXA
546 (red), goat-anti-rabbit ALEXA 488 (green), and
goat-anti-mouse IgG1 ALEXA 647 (blue) (Alexa, Invi-
trogen, Breda, The Netherlands). Next, the slides were
washedwith PBS. Images were captured with a confocal
laser scanning microscope (LSM510; Zeiss, Sliedrecht,
The Netherlands) in a multitrack setting (Department
of Cell Biology, LUMC).RESULTS
Primary Human Fibroblasts are Inefficiently
Targeted by Minor Histocompatibility Antigen-
Specific T Cells
To investigate whether nonhematopoietic tissues
are susceptible to the cytotoxic effect of alloreactive
MiHA-specific T cells, we exposed HLA-A*0201 pos-
itive, MiHA-positive primary human fibroblasts to
high avidity cytotoxic CD8 positive CTL clones
specific for the ubiquitously expressed HLA-A*0201-
binding MiHA LB-ADIR-1F, SMCY-HY, or allo-
HLA-A*0201, and examined cytotoxicity using
conventional 51Cr release assays and quantitative-
FACS analysis. As shown in Figure 1A, only 5% to
30% of the fibroblasts were lysed within 4 hours by
the T cell clones. In contrast, the same CTLs showed
efficient lysis of 60% to 80% of MiHA-positive EBV-
LCL, used as relevant substitutes for hematopoietic tu-
mor targets. To investigate whether the inability of the
MiHA-specific CTLs to efficiently attack MiHA-
positive primary human fibroblasts was due to subopti-
mal presentation of the relevant antigens on the cell
surface of the fibroblasts, we artificially increased the
numbers of peptide-MHC complexes available on the
HLA-A*0201 positive, LB-ADIR-1F negative, or pos-
itive fibroblasts by retroviral transduction with HLA-
A*0201 expression constructs and exogenous loading
with increasing concentrations of the relevant LB-
ADIR-1F-peptide. Transduction with HLA-A*0201
expression constructs resulted in a 3-fold increase in
the level of HLA-A*0201 expression compared to
transduction with an empty vector (mock) (HLA-
A*0201 mean fluorescence intensity [MFI] from 35 to
188). Whereas exogenous loading with up to 1 mM of
LB-ADIR-1F peptide of MiHA-negative EBV-LCL
resulted in efficient T cell-mediated cell death, exoge-
nous peptide loading of MiHA-negative, or MiHA-
positive fibroblasts did not increase the efficiency of
T cell-mediated cell death induction within 4 hours,
even afterHLA-A*0201 transduction (Figure 1B). Sim-
ilar results were obtained using SMCY-HY-specific
CTLclones (data not shown). These experiments illus-
trate that the cytotoxic activity of CTLs against pri-
mary human fibroblasts is not merely limited by the
number of peptide-MHC complexes on the target
cell surface. Because fibroblasts are large adherent cells,
we hypothesized that fibroblasts may be less efficiently
killed by T cells because of a shortage of T cell effector
molecules (granzymes, perforins, and death receptor li-
gands) available. However, increasing the amount of
effector T cells available for engaging the fibroblasts
by increasing E/T ratios up to 100/1 did not result in
increased lysis (Figure 1C, black line). Furthermore,
other large adherent HLA-A*0201 positive, LB-
ADIR-1F positive cell lines, including 2 renal cell
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Figure 1. Primary human fibroblasts are inefficiently targeted by minor
histocompatibility antigen-specific T cells cytotoxicity against primary
human fibroblasts of different minor histocompatibility antigen
(MiHA)-specific and allogeneic (allo)-HLA-specific T cell clones (CTLs)
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could be effectively killed by LB-ADIR-1F-positive
CTL clones within 4 hours (Figure 1C, grey lines).
These data illustrate that the inferior killing of fibro-
blasts was not caused by the size of the fibroblasts,
a shortage of available peptide-MHC complexes, or
shortage of effector T cells.Inferior Kill of Fibroblasts is not Caused by Lack
of T Cell Activation or Lack of Degranulation of
Cytotoxic Granules
Because the same CTLs that induced only mar-
ginal lysis of the primary human fibroblasts were able
to exert profound cytotoxicity against EBV-LCL, we
investigated whether the LB-ADIR-1F-specific
CTLs were activated upon HLA-A*0201-positive,
LB-ADIR-1F fibroblast encounter at an E/T-ratio of
1/1. Although the percentages of activated T cells
were higher upon EBV-LCL encounter, still more
than 50% of the T cells were antigen-specifically acti-
vated within 4 hours upon fibroblasts encounter, as
shown by the induction of expression of the activation
marker CD137 (Figure 2A) and a decrease in te-
tramer expression (Figure 2C). Furthermore, CTLs
produced IFNg upon MiHA-positive fibroblast
encounter within 4 hours, although the concen-
trations were lower compared to EBV-LCL encounter
(Figure 2B). Next, we examined whether this T cell ac-
tivation by the fibroblasts resulted in release of their
cytotoxic granules. As shown in Figure 2C, stimulation
with MiHA-positive fibroblasts resulted in degranula-
tion of 50% of the LB-ADIR-1F-specific CTLs after
4 hours, as visualized by the decrease in intracellularwas analyzed in 4-hour 51Cr release assays or by quantitative-
fluorescent activated cell sorter (FACS) analysis. Epstein-Barr virus-
transformed B cell lines (EBV-LCL) were used as hematopoietic control
cells. (A) Cytotoxicity against primary human fibroblasts (black lines) and
EBV-LCL (grey lines) expressing the relevant antigens of 3 CTL clones
specific for the MiHA LB-ADIR-1F (-), allo-HLA-A*0201 (C), or the
male-specific antigen SMCY-HY (:) was analyzed at different effector/
target (E/T) ratios. Primary human fibroblasts were less efficiently
attacked than EBV-LCL (mean6 SD of 3 experiments, P\.01). (B) Cy-
totoxicity of LB-ADIR-1F-specific CTLs against HLA-A*0201-positive,
LB-ADIR-1F-negative EBV-LCL (- - - -), HLA-A*0201-positive, LB-
ADIR-1F-negative fibroblasts (- -C- -), and HLA-A*0201-positive, LB-
ADIR-1F-positive fibroblasts, transduced with MOCK-nerve growth
factor receptor (NGFR) (:) or HLA-A*0201-NGFR (-), exogenously
loaded with increasing concentrations of the LB-ADIR-1F peptide, was
analyzed (E/Tratio 10/1). Increment of HLA-A*0201 expression and ex-
ogenous loading of the fibroblasts with the relevant LB-ADIR-1F peptide
did not result in increased cytotoxicity. Data shown aremeans6 SD of 3
replicates from a representative of 3 independent experiments. (C) Cy-
totoxicity of increasing numbers of LB-ADIR-1F-specific CTLs against
HLA-A*02 positive, LB-ADIR-1F positive primary human fibroblasts
(:) and other target cells, including EBV-LCL ( ), colon carcinoma
cell line ( ), and 2 renal cell carcinoma cell lines ( and ) was analyzed.
All target cells except the primary human fibroblastswere properly killed
within 4 hours. Data shown are a representative example from 3 inde-
pendent experiments.
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Figure 2. Inferior killing of fibroblasts is not caused by the absence of T cell activation or degranulation of cytotoxic granules. The activity of LB-ADIR-
1F-specific T cell clones (CTLs) against primary human fibroblasts was analyzed after 4 hours using different read-out systems. Epstein-Barr virus-trans-
formed B cell lines (EBV-LCL) were used as hematopoietic control cells. Activation of the CTLs in response to encounter of HLA*0201-positive,
LB-ADIR-1F-negative or positive primary human fibroblasts (black bars), or EBV-LCL (grey bars) (responder to stimulator [R/S] ratio 1/1) was deter-
mined by (A) flowcytometric analysis of cell surface CD137 expression, and by (B) IFNgamma (IFNg) production using IFNg ELISA. (C) The percentages
of activated and degranulating CTLs were determined by visualization of decreased intracellular expression of granzyme B (GZB) and perforin, or de-
creased tetramer staining, and induction of CD107a expression. A representative example of the flowcytometric analysis is shown. The dot plots shown
are gated based on CD3 staining. T cell activation and degranulation of at least 50% of the CTLs was observed after encounter of the primary human
fibroblasts. (D) The percentages of degranulating CTLs in response to increasing numbers of HLA*0201-positive, LB-ADIR-1F-negative (A), or positive
(-) primary human fibroblasts were examined. Increasing the amount of CTLs resulted in a decrease in the percentages of degranulating T cells.
1358 Biol Blood Marrow Transplant 18:1353-1367, 2012B. van der Zouwen et al.granzyme B (GZB) and perforin levels and the induced
expression of CD107a. In contrast, 85% to 90% of the
CTLs released their cytotoxic granules upon EBV-
LCL encounter. These observations also applied for
the other CTLs tested (data not shown). As shown inFigure 2D, increasing the amount of CTLs added to
the cultures resulted in a decrease in the percentages
of degranulating T cells, indicating that there is a lim-
iting amount of antigen and stimulator molecules
available. This can explain why increasing the amount
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supernatant-pretreated (black bars), IFNg-pretreated (with 500 pg/mL [diagonal lines], 1000 pg/mL [horizontal lines], or 10,000 pg/mL [vertical lines]
of IFNg) LB-ADIR-1F-positive, HLA*0201-positive primary human fibroblasts was analyzed in conventional 4 hour 51Cr release assays (E/Tratio 10/1).
Improved cytotoxicity of primary human fibroblasts was seen after pretreatment with pure IFNg or with IFNg-containing co-culture supernatants. (D)
Degranulation of the LB-ADIR-1F-specific CTL in response to encounter of IFNg-pretreated (lower panel) and non-treated (upper panel) HLA*A0201-
positive, LB-ADIR-1F-positive primary human fibroblasts (R/S ratio 1/3) was determined after 4 hours by flowcytometric analysis of intracellular expres-
sion of granzyme B (GZB), and degranulation visualized by CD107a expression. A representative example of the flowcytometric analysis is shown.
Uniform degranulation was observed after IFNg-pretreatment of the fibroblasts.
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sis (Figure 1C). These data illustrate that the CTLs
showed significant interplay with the MiHA-positive
fibroblasts, resulting in their activation and subsequent
degranulation. However, this crosstalk was not suffi-
cient for efficient target cell lysis within 4 hours of
co-culture.CTL-Mediated Lysis of Primary Human
Fibroblasts is Improved after Prolonged
Co-culture due to IFNg-Mediated Enhanced
Crosstalk
Because crosstalk between CTLs and fibroblasts
did not lead to efficient target cell lysis within 4 hours,
we investigated whether prolonged interaction could
Figure 4. IFNgamma (IFNg) pretreatment of primary human fibroblasts allows strong antigen-independent adhesion of minor histocompatibility an-
tigen (MiHA)-specific T cell clones (CTLs) to the fibroblasts. The percentages of adherent and non-adherent PKH26-labeled MiHA-specific CTLs to
1360 Biol Blood Marrow Transplant 18:1353-1367, 2012B. van der Zouwen et al.
Table 1. Surface Molecule Expression on Fibroblasts with or
without IFNg Pretreatment
CD-Number Antigen Name
Expression (MFI)
IFNg 2 IFNg +
CD2 LFA-2 – –
CD11a LFA-1 – –
CD11b a-M-integrine – –
CD15 Leu-M1 – –
CD18 b2-integrine – –
CD31 PECAM-1 – –
CD43 Leukosialine + (106) + (112)
CD49d VLA4a + (95) + (100)
CD49e VLA5a + (192) + (220)
CD49f VLA6a + (151) + (178)
CD50 ICAM-3 + (98) + (88)
CD54 ICAM-1 2 (68) ++ (527)
CD57 HNK-1 – –
CD58 LFA-3 + (116) + (116)
CD90 Thy-1 ++ (7606) ++ (5993)
CD62E E-selectine – –
CD62L L-selectine – –
CD62P P-selectine – –
CD102 ICAM-2 – –
CD103 Integrine-a-E-b-7 – –
CD106 VCAM-1 – –
CD166 ALCAM + (103) + (101)
MFI indicates mean fluorescence intensity; IFNg, IFNgamma.
2 5 negative (MFI <70).
+ 5 positive (MFI $80).
++ 5 high expression (MFI $500).
The ICAM-1 result is emphasized in bold.
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broblasts by performing 8 and 20 hours cytotoxicity as-
says. As shown in Figure 3A, prolonged co-culture of
fibroblasts with either MiHA-specific or allo-HLA-
A*0201-specific CTLs resulted in increased lysis of
the HLA-A*0201-positive/MiHA-positive fibroblasts
(solid lines), whereas no increase in a specific lysis by
the negative HA-1-specific T cell clone was observed
(dashed line). Next, we wondered whether this in-
creased, Ag-specific lysis after prolonged co-culture
was the result of the local formation of a more proin-
flammatory environment due to secreted cytokines.
We already demonstrated that CTLs started to pro-
duce IFNg upon fibroblast encounter (Figure 2B),
and analysis of longer culture periods showed increas-
ing levels of IFNg up to 1400 pg/mL after 20 hours
(Figure 3B). To examine the role of the secreted cyto-
kines, we pretreated fibroblasts with supernatants har-
vested from 20 hours co-cultures of theMiHA-specific
CTLs withMiHA-positive fibroblasts, and tested their
susceptibility to CTL-induced lysis in 4 hours cytotox-
icity assays. Pretreatment with these supernatants was
sufficient to significantly increase 4 hours cytotoxicity
(Figure 3C). To investigate the specific role of IFNg,
we examined whether pretreatment of the fibroblasts
solely with IFNg (500, 1000, and 10,000 pg/mL for
24 hours) resulted in similar sensitization of the fibro-
blasts to CTL-mediated lysis. As shown in Figure 3C,
pretreatment of the fibroblasts with only 500 pg/mL
IFNg was sufficient to increase their sensitivity to
T cell-mediated cell death to the same extent as was ob-
servedwhenfibroblasts were pretreatedwith the super-
natants. As shown in Figure 3D, IFNg pretreatment of
LB-ADIR-1F-positive fibroblasts also increased their
capacity to activate all LB-ADIR-1F-specific T cells
as reflectedby theiruniformdegranulation after4hours
of co-culture. These data illustrate that, during pro-
longed co-culture,CTLsproduced IFNg leading to in-
creased interplay between the CTL and the fibroblast,
which resulted in increased susceptibility to CTL-
mediated lysis of the primary human fibroblasts.IFNg Pretreatment of Primary Human
Fibroblasts Allows Formation of High Avidity
Interactions with Minor Histocompatibility
Antigen-Specific T Cells
Because IFNg pretreatment of fibroblasts resulted
in increased interplay with the CTLs leading to theira monolayer of HLA-A*0201-positive, MiHA-negative, or MiHA-positive prim
layer (adherent T cells) and above the monolayer (non-adherent T cells) using fl
target [E/T] ratio 3/1). Ten to 12 regions per glass slide were analyzed. (A) Repr
T cells was limited. (B) The percentages of adherent and non-adherent PKH2
pictures), or non-treated (left pictures) HLA-A*0201-positive, MiHA-negative
tative images for the number of adhering CTLs at the level of the fibroblast laye
specific CTLs to the IFNg pretreated (black bar), or non-treated (white bar
(means6 SD). IFNg pretreatment of the fibroblasts significantly increased the
expression (n 5 3, P\.01).
=increased susceptibility to T cell-induced cell death,
we analyzed in detail interactions between the 2 cell
types using confocal fluorescent microscopy under dif-
ferent conditions. First, we examined under steady
state conditions the interactions between HLA-
A*0201-positive, MiHA-negative or MiHA-positive
fibroblasts, and MiHA-specific CTLs, which were la-
beled with the fluorescent dye PKH26. After 1 to
2 hours of co-culture, the percentages of CTLs
strongly adhering to the fibroblasts were assessed us-
ing fluorescent confocal microscopy. To assess this,
we determined the number of T cells showing red fluo-
rescence in focus at the level of the fibroblasts mono-
layer (adherent T cells) and above the monolayer
(nonadherent T cells). As demonstrated in Figure 4A
to C, only 20% of the CTLs strongly adhered to the
fibroblasts layer under steady-state conditions, irre-
spective whether they were MiHA-negative or posi-
tive, indicating that only limited interactions
occurred between the 2 cell types. Next, we examined
interactions between CTLs and fibroblasts, which
were pretreated with IFNg to mimic proinflammatoryary human fibroblasts was analyzed at the level of the fibroblasts mono-
uorescent confocal microscopy after 1 to 2 hours of co-culture (effector/
esentative images are shown for both levels. The percentage of adherent
6-labeled MiHA-specific CTLs to a monolayer of IFNg pretreated (right
, or MiHA-positive primary human fibroblasts were analyzed. Represen-
r are shown. (C) Cumulative data of the percentages of adherent MiHA-
) MiHA-negative fibroblasts of 3 independent experiments are shown
percentages of CTLs adhering to the fibroblasts independent of antigen
Figure 5. ICAM-1 is a key molecule in the interaction of minor histocompatibility antigen (MiHA)-specific T cells with fibroblasts mediating efficient
T cell activation and target cell lysis. The activity of different MiHA-specific T cell clones (CTLs) against HLA-A*0201-positive primary human fibroblasts,
which were retrovirally transduced with mock-nerve growth factor receptor (NGFR), HLA-A*0201-NGFR, or ICAM-1-NGFR expression constructs
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treatment ofHLA-A*0201-positiveMiHA-negative fi-
broblasts strongly increased the capacity of the CTLs
to firmly adhere to them as indicated by the red fluo-
rescence in focus at the fibroblast level, even in the ab-
sence of specific antigen recognition. Similarly, strong
increases in the number of CTLs adhering to the
MiHA-positive fibroblasts were observed, although
quantitative analysis was hampered by the interference
of T cell-mediated target cell lysis (Figure 4B, lower
panel). These data illustrate that IFNg pretreatment
of the fibroblasts allowed strong adherence of the
CTLs to the fibroblasts, which enhanced their cross-
talk leading to increased susceptibility for T cell-
mediated lysis.
Efficient T Cell Activation and Target Cell Lysis
is Primarily Dependent on ICAM-1 Expression
on MiHA-Positive Fibroblasts
Next, we examined differential surface expression
of a panel of adhesion and co-stimulatory molecules
known to be involved in T cell-target cell interactions
on fibroblasts before and after IFNg pretreatment. In
addition to increased expression of MHC class I and
II, only ICAM-1 (CD54) was strongly upregulated af-
ter IFNg pretreatment (Table 1). Although we already
demonstrated that solely increasing the amount of the
specific HLA molecules presenting the relevant CTL
epitopes (HLA-A*0201) did not increase susceptibility
toCTL-mediated lysis (Figure 1B), we investigated the
individual role of ICAM-1 and HLA-A*0201 in CTL-
fibroblast interaction, by inducing expression of
ICAM-1 andHLA-A*0201 inMiHA-negative andpos-
itive fibroblasts by retroviral transduction.T cell clones
showed profound expression of the ICAM-1-ligand
lymphocyte function-associated antigen-1 (LFA-1/
CD11a) (data not shown). Figure 5A shows the in-
creased expression of NGFR, HLA-A*0201 (from 35
to 188) and ICAM-1 (from 6 to 297) after retroviral
transduction. As shown in Figure 5B and C, solely,
the induction of ICAM-1 expression on the surface of
MiHA-negative or MiHA-positive fibroblasts was suf-was analyzed using different read-out systems. (A) Mean fluorescence intensity
NGFR (grey lines), HLA-A*0201-NGFR (black lines), or ICAM-1-NGFR (red lin
expression levels of NGFR, HLA-A*0201, and ICAM-1 were observed. Data sh
The percentages of adherent and non-adherent PKH26-labeled MiHA-specific C
positive primary human fibroblasts were analyzed at the level of the fibroblasts m
culture (effector/target [E/T] ratio 3/1). Ten to 12 regions per glass slide were
monolayers of mock transduced (left pictures), HLA-A*0201 transduced (m
positive, MiHA-negative (upper panel), or MiHA-positive (lower panel) prima
specific CTL clones adhering to monolayers of HLA-A*0201-positive, MiHA-n
(IFNg) pretreatment of the fibroblasts or induction of ICAM-1 expression sig
independent of antigen expression (n 5 3, P \ .01). (D-G) Cytotoxicity o
transduced HLA*0201-positive, LB-ADIR-1F-positive fibroblasts, which were
analyzed in conventional 4-hour 51Cr release assays (E/T ratio 10/1). Improve
ICAM-1 expression, comparable with the level of cytotoxicity seen after IFN
mediated cytotoxicity (E), T cell degranulation (F) and activation (G) again
pretreated fibroblasts (black bars) could be blocked by the addition of ICAM-1
from a representative of 3 independent experiments.
=ficient to allow firm adherence of the T cells to the fi-
broblasts to a similar extent as seen after IFNg
pretreatment, whereas increased expression of HLA-
A*0201 did not affect the numbers of adherent CTLs.
In concordance with the previous observations, in-
troduction of ICAM-1 expression on MiHA-positive
human fibroblasts resulted in increased susceptibility
to CTL-mediated cytotoxicity after 4 hours
(Figure 5D). To investigate whether the increased
levels of CTL-mediated cytotoxicity after IFNg pre-
treatment could be attributed to the ICAM-1 upregu-
lation, we blocked the ICAM-1-LFA-1 interactions
using anti-ICAM-1 mAbs. As shown in Figure 5E,
blockade of ICAM-1 significantly diminished the
CTL-mediated lysis of IFNg-pretreated and ICAM-1
transduced fibroblasts. Moreover, blockade of ICAM-
1 also diminished activation of LB-ADIR-1F-specific
T cells as reflected by reduction of the numbers of de-
granulating CTLs (Figure 5F) and the numbers of
CD137 expressing CTLs (Figure 5G). Altogether,
these data show that ICAM-1 expression on primary
human fibroblasts is a key factor in the interaction
with MiHA-specific T cells determining the efficiency
of T cell activation and target cell lysis.
Co-Localization of T Cell Infiltration and
Increased ICAM-1 Expression on Epithelial Basal
Layer Keratinocytes in Skin Biopsies of Patients
with aGVHD
To investigate whether ICAM-1 expression is asso-
ciated with T cell-mediated target cell damage in vivo,
we performed multicolor fluorescent confocal micros-
copy in skin biopsies of healthy controls and patients
with acute skin GVHD after alloSCT (n 5 5). In
Figure 6, fluorescent images of these skin biopsies are
shown stained for T cell infiltration (red) and ICAM-1
expression (green) in the dermis and epidermis
regions. In normal skin biopsies taken from healthy
individuals, T cells residing in the dermal layer of the
skin are frequently detected. In these regions, as well
as in regions without T cell infiltration, no ICAM-1 ex-
pression on the surrounding nonhematopoietic cells(MFI) of expression levels of NGFR, HLA-A*0201, and ICAM-1 in mock-
es) transduced fibroblasts was analyzed by flowcytometry. Increased MFI
own are representative examples of 3 independent experiments. (B-C)
TLs to a monolayer of HLA-A*0201-positive, MiHA-negative, or MiHA-
onolayer using confocal fluorescent microscopy after 1 to 2 hours of co-
analyzed. (B) Representative images are shown of CTLs adhering to the
iddle pictures), or ICAM-1 transduced (right pictures) HLA-A*0201-
ry human fibroblasts. (C) Cumulative data of the percentages of MiHA-
egative fibroblasts of 3 independent experiments are shown. IFNgamma
nificantly increased the percentages of CTLs adhering to the fibroblasts
f LB-ADIR-1F-specific CTL against mock, HLA-A*0201, or ICAM-1-
non-pretreated or pretreated with IFNg (200 U/mL for 48 hours) was
d cytotoxicity of primary human fibroblasts was seen after induction of
g-pretreatment of the fibroblasts (D) (n 5 3, P\ .01). Improved CTL-
st both ICAM-1 transduced fibroblasts and Mock transduced IFNg-
-blocking mAbs (white bars). Values are means6 SD of 3 replicate wells
Figure 6. Co-localization of T cell infiltration and increased ICAM-1 expression on nonhematopoietic tissue in skin biopsies of patients with acute
graft-versus-host disease (aGVHD). The expression and localization of ICAM-1 (green), CD3 (T cells, red), and cytokeratin (keratinocytes, blue) ex-
pression in normal skin biopsies (A-B) and in skin biopsies of patients suffering from acute skin GVHD (C-F) was determined using fluorescent immu-
nohistochemistry. (A-B) Representative images (250 magnification) of the epithelial (Ep) and dermal layer (Derm) of normal human skin are shown for
regions with (A) or without (B) residing T cells (arrows) show no ICAM-1 expression on the surrounding nonhematopoietic cells. Circular green staining
in the Derm represents vascular structures. Representative images (250 magnification) of the epithelial (Ep) and dermal layer (Derm) of human skin at
the site of aGVHD of 2 patients are shown for regions of the epithelial basal layer where T cell infiltration was present (C-D) and regions of the same
corresponding biopsies in which no T cell infiltration was observed (E-F). In the regions in which infiltration of T cells and damage to the epithelial layers
was observed (C-D), ICAM-1 expression was upregulated on the surrounding nonhematopoietic cells in the basal layer. In contrast, regions in the same
biopsies in which no T cell infiltrationwas observed showed only minimal to absent ICAM-1 expression on the cells in the basal layer (E-F). To analyze the
activation status of the residing/infiltrating T cells we performed a CD3 (blue), HLA-class-II (red), and cytokeratin (green) triple staining.Whereas T cells
residing in normal skin showed no co-expression of HLA-class-II (G), T cells infiltrating in the skin GVHD lesion (H) were activated as indicated by their
co-expression of HLA-class II.
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skin GVHD lesions of patients who underwent al-
loSCT, regions could be identified in which massive
T cell infiltrates were present (Figure 6C, D) as well
as regions of the same biopsies showing no T cell infil-
tration (Figure 6E,F). In the regionswith large amounts
ofT cells infiltrating both the dermis and epidermis and
inducing damage to the epithelial layers, ICAM-1 ex-
pression was clearly upregulated on the surrounding
nonhematopoietic cells in the basal layer (Figure 6C,
D). In contrast, in surrounding parts in which no or
only limited numbers of T cells were present, no signif-
icant ICAM-1expressionon thenonhematopoietic cells
in the basal layer was detected (Figure 6E, F). To ana-
lyze the activation state of the T cells in biopsies from
normal skin and in biopsies taken from skin GVHD le-
sions, we determined the HLA-class II expression on
CD3positiveT cells. As shown inFigure 6G,T cells re-
siding in normal skin were not activated as indicated by
the absence of HLA-class II expression, whereas the
majority of T cells in the dermal infiltrate in the
GVHD biopsies showed clear co-expression of CD3
and HLA-class II reflected by the pink color
(Figure 6H). These data illustrate that there is an asso-
ciation between the magnitude of the local T cell re-
sponse, the coinciding formation of a local
proinflammatory environment by the activated T cells,
and ICAM-1 expression on nonhematopoietic tissues in
the human skin during aGVHD.DISCUSSION
The aim of the current study was to investigate in
detail the reactivity of alloreactive T cells specific for
ubiquitously expressed MiHA against nonhemato-
poietic patient-derived target cells. We demonstrated
that in vitro reactivity of MiHA-specific T cells against
nonhematopoietic targets cannot solely be predicted
by their antigen-specificity and confirmed that adhe-
sion molecule expression on the target cells was pivotal
to facilitate the formation of high avidity interactions
necessary for proper target cell destruction [20-27].
ICAM-1 expression on primary human fibroblasts
was demonstrated to be a key molecule mediating
these high avidity interactions. Because fibroblasts do
not express ICAM-1 under noninflammatory steady-
state conditions, only limited numbers of T cells
adhered to the fibroblasts and, although these interac-
tions did initialize crosstalk between the cells, this was
not enough for efficient target cell destruction. During
extended co-culture, crosstalk was intensified fueled by
IFNg that was locally produced by the activated T cells
leading to ICAM-1 expression on the fibroblasts and
strong adherence to the T cells, which in the end ren-
dered the fibroblasts sensitive to T cell-mediated lysis.
Moreover, we provided supporting evidence for therole of ICAM-1 expression on nonhematopoietic tis-
sues during ongoingGVHD responses in vivo by dem-
onstrating co-localization of infiltration of activated T
cells and increased ICAM-1 expression on the epithe-
lial cells of the basal layer in skin biopsies of patients
with aGVHD.
This study illustrates that, in the absence of local
danger signals, low expression of ICAM-1 on nonhe-
matopoietic GVHD target tissues prevents the occur-
rence of high avidity interactions with potent
alloreactive T cells, thereby sparing these normal tis-
sues. This can explain the clinical observations that
high frequencies of T cells expressing specific T cell
receptors with high affinity for MiHA with ubiquitous
expression in both hematopoietic and nonhemato-
poietic tissues can circulate in patients showing GVL
reactions in the absence of GVHDor with only limited
GVHD [13-15]. When danger signals are present and
ICAM-1 expression on the target cells is induced,
strong adherence to the T cells is facilitated allowing
target cell destruction. In our in vitro model, as well
as in previous studies, the importance of the local
proinflammatory cytokine milieu produced by the ac-
tivated T cells in the induction of ICAM-1 expression
is demonstrated [11,24,29,32,39,40].
Recent studies have shown the importance of the
leukocyte function-associated antigen 1 (LFA-1)-
ICAM-1 interaction between T cells and their targets
cells for the execution of a proper cytotoxic effect
[22-25,41-43]. There is strong evidence that the
engagement of LFA-1 on the CTL by ICAM-1 on
the target cells is essential for T cell activation and es-
pecially for directing the release of cytolytic granules
toward the antigen-bearing tumor cells and the subse-
quent effective destruction of these cells by the CTLs
[7,9,10,25,41]. Moreover, the ability of tumor cells to
escape T cell immunity by ICAM-1 downregulation il-
lustrates the importance of ICAM-1 expression on tar-
get cells in their susceptibility CTL attack [44-46].
In the current study, we demonstrated the absence
of ICAM-1 expression on nonhematopoietic cells in
skin biopsies of healthy control individuals, even at
the regions in the dermis in which low numbers of
T cells were residing, whereas profound ICAM-1 ex-
pression on the nonhematopoietic cells in the epider-
mis was demonstrated in biopsies taken from focal
skin GVHD lesions at regions with profound infiltra-
tion of activated T cells. At the time of alloSCT, dan-
ger signals may be abundant due to the conditioning
regimen preceding the transplantation, infections
with pathogens, and concurrent inflammatory re-
sponses [31,47,48]. Moreover, malignant cells or
professional antigen presenting cells (APCs) of the
patient present in the skin can locally interact with
T cells that reside in these tissues leading to T cell
activation, proinflammatory cytokine production,
upregulation of adhesion molecule expression, and
1366 Biol Blood Marrow Transplant 18:1353-1367, 2012B. van der Zouwen et al.subsequent local amplification of the T cell response
and tissue damage (GVHD). This may explain why
infusion of mature donor T cells with or early after
alloSCT often results in the induction of GVHD
[11]. On the other hand, delayed application of DLI
at 3 to 6 months after T cell-depleted alloSCT is asso-
ciated with less severe GVHD, most likely because the
tissue destruction by conditioning regimen has been
repaired and antigen-presenting cells (APCs) of pa-
tient origin in the tissues are gradually replaced by do-
nor cells [49,50]. In the absence of local danger signals,
potent alloreactive donor T cells will most likely only
briefly interact with the nonhematopoietic target cells
and the high avidity interactions necessary for target
cell destruction and local amplification of the T cell
response will not be formed. Thus, after application
of delayed DLI under appropriate circumstances,
targeting of MiHA with a broad expression profile
may result in specific GVL reactivity without GVHD.
Another possibility to achieve specific GVL reac-
tivity without GVHD induction is adoptive transfer
of donor T cells preferentially directed against hema-
topoietic tissues of the patient [19,51,52]. One
possible strategy that has been exploited is the
negative selection of potent GVHD-reactive donor-
derivedT cells by depletingT cells that show reactivity
against patient-derived fibroblasts [19]. However, de-
spite the lack of in vitro reactivity against patient-
derived fibroblasts, these selected donor-derived
T cells gave rise to significant GVHD after adoptive
transfer. Based on our data showing that the presence
of proper peptide-MHC complexes and also ICAM-1
expression is necessary for proper T cell reactivity
upon fibroblast encounter, pretreatment with IFNg
and longer assay periods could increase the sensitivity
of this negative selection strategy using patient-
derived fibroblasts as stimulator cells.
In conclusion, this study demonstrates that in vivo
reactivity of MiHA-specific T cells leading to GVHD
cannot solely be predicted by their antigen-specificity,
but is also determined by adhesion molecule expres-
sion on the GVHD target tissues, which is dependent
on the local proinflammatory environment of the host
target tissues. Based on these findings, we hypothesize
that in the situation of minimal residual disease under
noninflammatory circumstances, application of un-
modified DLI containing a broad repertoire of T cell
specificities may mediate a specific GVL response in
the absence of GVHD.ACKNOWLEDGMENTS
Financial disclosure: The authors declare no com-
peting financial interests.
Authorship contributions: Boris van der Zouwen,
Peter A. von dem Borne, J.H. Frederik Falkenburg,
and Inge Jedema designed the research; Boris van derZouwen, Alwine B. Kruisselbrink, Ekaterina S. Jorda-
nova, and Caroline E. Rutten performed the research;
Boris van der Zouwen, Alwine B. Kruisselbrink,
Ekaterina S. Jordanova, Peter A. von dem Borne,
J.H. Frederik Falkenburg, and Inge Jedema analyzed
data; and Boris van der Zouwen, J.H. Frederik Falken-
burg, and Inge Jedema wrote the article.REFERENCES
1. Appelbaum FR. The current status of hematopoietic cell trans-
plantation. Annu Rev Med. 2003;54:491-512.
2. Kolb HJ. Graft-versus-leukemia effects of transplantation and
donor lymphocytes. Blood. 2008;112:4371-4383.
3. Falkenburg JH, van de Corput L, Marijt EW, Willemze R.
Minor histocompatibility antigens in human stem cell transplan-
tation. Exp Hematol. 2003;31:743-751.
4. Feng X, Hui KM, Younes HM, Brickner AG. Targeting minor
histocompatibility antigens in graft versus tumor or graft versus
leukemia responses. Trends Immunol. 2008;29:624-632.
5. Mullally A, Ritz J. Beyond HLA: the significance of genomic
variation for allogeneic hematopoietic stem cell transplantation.
Blood. 2007;109:1355-1362.
6. Irle C, Beatty PG,Mickelson E, Thomas ED, Hansen JA. Allor-
eactive T cell responses betweenHLA-identical siblings. Detec-
tion of anti-minor histocompatibility T cell clones induced
in vivo. Transplantation. 1985;40:329-333.
7. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hemato-
poiesis-restricted minor histocompatibility antigens HA-1- or
HA-2-specific T cells can induce complete remissions of re-
lapsed leukemia. Proc Natl Acad Sci U S A. 2003;100:2742-2747.
8. Riddell SR, Murata M, Bryant S, Warren EH. Minor histocom-
patibility antigens–targets of graft versus leukemia responses. Int
J Hematol. 2002;76(Suppl 2):155-161.
9. Riddell SR, Berger C,MurataM, Randolph S,Warren EH. The
graft versus leukemia response after allogeneic hematopoietic
stem cell transplantation. Blood Rev. 2003;17:153-162.
10. Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of
the graft-versus-host activities of cytotoxic T cells specific for
minor histocompatibility antigens. Nat Med. 2002;8:410-414.
11. Ferrara JL, Levine JE, Reddy P,Holler E. Graft-versus-host dis-
ease. Lancet. 2009;373:1550-1561.
12. Goulmy E, Gratama JW, Blokland E, Zwaan FE, van Rood JJ.
A minor transplantation antigen detected by MHC-restricted
cytotoxic T lymphocytes during graft-versus-host disease.
Nature. 1983;302:159-161.
13. Randolph SS, Gooley TA, Warren EH, Appelbaum FR,
Riddell SR. Female donors contribute to a selective graft-versus-
leukemia effect inmale recipients ofHLA-matched, related hema-
topoietic stem cell transplants. Blood. 2004;103:347-352.
14. van Bergen CA, Kester MG, Jedema I, et al. Multiple myeloma-
reactive T cells recognize an activation-induced minor
histocompatibility antigen encoded by the ATP-dependent in-
terferon-responsive (ADIR) gene. Blood. 2007;109:4089-4096.
15. Van Bergen CA, Rutten CE, Van Der Meijden ED, et al. High-
throughput characterization of 10 newminor histocompatibility
antigens by whole genome association scanning. Cancer Res.
2010;70:9073-9083.
16. BleakleyM, Riddell SR.Molecules andmechanisms of the graft-
versus-leukaemia effect. Nat Rev Cancer. 2004;4:371-380.
17. MarkiewiczM, SiekieraU,Karolczyk A, et al. Immunogenic dis-
parities of 11 minor histocompatibility antigens (mHAs) in
HLA-matched unrelated allogeneic hematopoietic SCT. Bone
Marrow Transplant. 2009;43:293-300.
18. Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P,
Goulmy E. Tetrameric HLA class I-minor histocompatibility
antigen peptide complexes demonstrate minor histocompatibil-
ity antigen-specific cytotoxic T lymphocytes in patients with
graft-versus-host disease. Nat Med. 1999;5:839-842.
Biol Blood Marrow Transplant 18:1353-1367, 2012 1367GVHD Reactivity of Alloreactive Effector T Cells19. Warren EH, Fujii N, Akatsuka Y, et al. Therapy of relapsed leu-
kemia after allogeneic hematopoietic cell transplantation with
T cells specific for minor histocompatibility antigens. Blood.
2010;115:3869-3878.
20. Dustin ML, Long EO. Cytotoxic immunological synapses.
Immunol Rev. 2010;235:24-34.
21. van der Merwe PA. Formation and function of the immunolog-
ical synapse. Curr Opin Immunol. 2002;14:293-298.
22. MakgobaMW, SandersME,Ginther LuceGE, et al. Functional
evidence that intercellular adhesionmolecule-1 (ICAM-1) is a li-
gand for LFA-1-dependent adhesion in T cell-mediated cyto-
toxicity. Eur J Immunol. 1988;18:637-640.
23. Suranyi MG, Bishop GA, Clayberger C, et al. Lymphocyte ad-
hesion molecules in T cell-mediated lysis of human kidney cells.
Kidney Int. 1991;39:312-319.
24. Symington FW, Santos EB. Lysis of human keratinocytes by al-
logeneic HLA class I-specific cytotoxic T cells. Keratinocyte
ICAM-1 (CD54) and T cell LFA-1 (CD11a/CD18) mediate en-
hanced lysis of IFN-gamma-treated keratinocytes. J Immunol.
1991;146:2169-2175.
25. Berg NN, Ostergaard HL. Characterization of intercellular ad-
hesion molecule-1 (ICAM-1)-augmented degranulation by cy-
totoxic T cells. ICAM-1 and anti-CD3 must be co-localized
for optimal adhesion and stimulation. J Immunol. 1995;155:
1694-1702.
26. JenkinsMR,GriffithsGM.The synapse and cytolyticmachinery
of cytotoxic T cells. Curr Opin Immunol. 2010;22:308-313.
27. Jenkinson SR,WilliamsNA,MorganDJ. The role of intercellu-
lar adhesionmolecule-1/LFA-1 interactions in the generation of
tumor-specific CD81 T cell responses. J Immunol. 2005;174:
3401-3407.
28. Schmid DA, Irving MB, Posevitz V, et al. Evidence for a TCR
affinity threshold delimiting maximal CD8 T cell function.
J Immunol. 2010;184:4936-4946.
29. De Bueger M, Bakker A, Van Rood JJ, Goulmy E. Minor histo-
compatibility antigens, defined by graft-vs.-host disease-derived
cytotoxic T lymphocytes, show variable expression on human
skin cells. Eur J Immunol. 1991;21:2839-2844.
30. Lawley TJ, Kubota Y. Cell adhesion molecules and cutaneous
inflammation. Semin Dermatol. 1991;10:256-259.
31. Matzinger P. The danger model: a renewed sense of self. Science.
2002;296:301-305.
32. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol.
2007;7:340-352.
33. GriffioenM, van EgmondHM, Barnby-Porritt H, et al. Genetic
engineering of virus-specific T cells with T-cell receptors recog-
nizingminor histocompatibility antigens for clinical application.
Haematologica. 2008;93:1535-1543.
34. HeemskerkMH, de Paus RA, LurvinkEG, et al. DualHLA class
I and class II restricted recognition of alloreactive T lympho-
cytes mediated by a single T cell receptor complex. Proc Natl
Acad Sci U S A. 2001;98:6806-6811.
35. Heemskerk MH, Hoogeboom M, Hagedoorn R, Kester MG,
Willemze R, Falkenburg JH. Reprogramming of virus-specific
T cells into leukemia-reactive T cells using T cell receptor
gene transfer. J Exp Med. 2004;199:885-894.
36. Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA, et al.
Minor histocompatibility antigen-specific T cells with multiple
distinct specificities can be isolated by direct cloning of
IFNgamma-secreting T cells from patients with relapsed leuke-mia responding to donor lymphocyte infusion. Leukemia. 2005;
19:83-90.
37. Meadows L, Wang W, den Haan JM, et al. The HLA-A*0201-
restricted H-Y antigen contains a posttranslationally modified
cysteine that significantly affects T cell recognition. Immunity.
1997;6:273-281.
38. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of
antigen-specific T lymphocytes. Science. 1996;274:94-96.
39. Broady R, Yu J, Chow V, et al. Cutaneous GVHD is associated
with the expansion of tissue-localized Th1 and not Th17 cells.
Blood. 2010;116:5748-5751.
40. Das H, Imoto S, Murayama T, et al. Kinetic analysis of cytokine
gene expression in patients with GVHD after donor lymphocyte
infusion. Bone Marrow Transplant. 2001;27:373-380.
41. Anikeeva N, Somersalo K, Sims TN, Thomas VK, Dustin ML,
Sykulev Y. Distinct role of lymphocyte function-associated anti-
gen-1 in mediating effective cytolytic activity by cytotoxic
T lymphocytes. Proc Natl Acad Sci U S A. 2005;102:6437-6442.
42. Galocha B, Lopez D, Lopez de Castro JA. Clonal heterogeneity
in LFA-3 and ICAM-1 requirement for lysis by alloreactive
T lymphocytes. J Immunol. 1993;150:1653-1662.
43. Rosato A, Mandruzzato S, Bronte V, et al. Role of anti-LFA-1
and anti-ICAM-1 combined MAb treatment in the rejection of
tumors induced by Moloney murine sarcoma virus (M-MSV).
Int J Cancer. 1995;61:355-362.
44. Gregory CD,Murray RJ, Edwards CF, Rickinson AB. Downre-
gulation of cell adhesion molecules LFA-3 and ICAM-1 in
Epstein-Barr virus-positive Burkitt’s lymphoma underlies tumor
cell escape from virus-specific T cell surveillance. J Exp Med.
1988;167:1811-1824.
45. Anichini A, Mortarini R, Alberti S, Mantovani A, Parmiani G.
T-cell-receptor engagement and tumor ICAM-1 up-regulation
are required to by-pass low susceptibility of melanoma cells to
autologous CTL-mediated lysis. Int J Cancer. 1993;53:
994-1001.
46. B€ohmig GA, Kovarik J, Holter W, Pohanka E, Zlabinger GJ.
Specific down-regulation of proliferative T cell alloresponsive-
ness by interference with CD2/LFA-3 and LFA-1/ICAM-1
in vitro. J Immunol. 1994;152:3720-3728.
47. Ferrara JL, Cooke KR, Teshima T. The pathophysiology of
acute graft-versus-host disease. Int J Hematol. 2003;78:181-187.
48. Wilhelm K, Ganesan J, M€uller T, et al. Graft-versus-host dis-
ease is enhanced by extracellular ATP activating P2X7R. Nat
Med. 2010;16:1434-1438.
49. Auffermann-Gretzinger S, Eger L, Bornh€auserM, et al. Fast ap-
pearance of donor dendritic cells in human skin: dynamics of
skin and blood dendritic cells after allogeneic hematopoietic
cell transplantation. Transplantation. 2006;81:866-873.
50. von dem Borne PA, Beaumont F, Starrenburg CW, et al. Out-
comes after myeloablative unrelated donor stem cell transplan-
tation using both in vitro and in vivo T-cell depletion with
alemtuzumab. Haematologica. 2006;91:1559-1562.
51. Falkenburg JH, Wafelman AR, Joosten P, et al. Complete re-
mission of accelerated phase chronic myeloid leukemia by treat-
ment with leukemia-reactive cytotoxic T lymphocytes. Blood.
1999;94:1201-1208.
52. Jedema I, Meij P, Steeneveld E, et al. Early detection and rapid
isolation of leukemia-reactive donorT cells for adoptive transfer
using the IFN-gamma secretion assay. Clin Cancer Res. 2007;
13(2 Pt 1):636-643.
